# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Kennedy disease

Spinobulbar muscular atrophy (SBMA)Bulbospinal amyotrophy, X-Linked
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 30 results.
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Status: Recruiting
Last Changed: Aug 13, 2018
First Received: Jun 13, 2018
Disease(s): Spinal and Bulbar Muscular Atrophy
Intervention(s): Leuprorelin Acetate
Locations: Takeda Selected Site, Tokyo, Japan
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
Status: Recruiting
Last Changed: Sep 18, 2019
First Received: Jul 26, 2018
Disease(s): Solid Tumor, Androgen Receptor Gene Overexpression
Intervention(s): SEVI-D (Seviteronel in combination with dexamthasone)
Locations: St Vincent's Hospital, Darlinghurst, New South Wales, Australia
Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Status: Recruiting
Last Changed: Jul 02, 2020
First Received: Apr 28, 2014
Disease(s): Spinal and Bulbar Muscular Atrophy, Motor Neuron Disease
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study on Androgen Receptor and Triple Negative Breast Cancer
Status: Recruiting
Last Changed: Aug 26, 2019
First Received: Dec 26, 2017
Disease(s): Breast Cancer Female, Triple Negative and Androgen Receptor Positive
Intervention(s): Darolutamide, Capecitabine
Locations: Centre François Baclesse, Caen, France
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Status: Recruiting
Last Changed: Jun 07, 2019
First Received: Feb 24, 2016
Disease(s): Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Intervention(s): Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
Status: Recruiting
Last Changed: May 15, 2020
First Received: Jul 02, 2017
Disease(s): Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
Intervention(s): Alpelisib, Enzalutamide
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Status: Not yet recruiting
Last Changed: Jun 04, 2020
First Received: Apr 06, 2020
Disease(s): Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer
Intervention(s): Darolutamide, Enzalutamide
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
University of Minnesota, Minneapolis, Minnesota, United States
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Status: Recruiting
Last Changed: Nov 22, 2019
First Received: Jan 11, 2017
Disease(s): Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Intervention(s): GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Locations: City of Hope Comprehensive Cancer Center, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting
Last Changed: May 07, 2020
First Received: Feb 21, 2020
Disease(s): Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Intervention(s): Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: Apr 25, 2018
Disease(s): Prostate Cancer
Intervention(s): Flutamide, Placebo
Locations: SKCCC at Johns Hopkins, Baltimore, Maryland, United States